Background: 

For a long time, phenomenon of defective immune-surveillance in cancer patients from pathological standpoint was not elucidated. I have reported 1985 that lowering seral cyclic AMP is biochemical reason of defective immunesurveillance from adoptive lymphocyte immunotherapy experiment among cancer patients. Recently, Honjo Tasku et al., reported why T cell don’t attack cancer cells by the covering of PD-L1 on its receptor of PD-1. This is also one of defective immune-surveillance from cellular side. I have recently surveyed the correlation between seral cyclic AMP concentration and immune activity in cancer patients. I have confirmed the biochemical reason of lowering cyclic AMP leads to seral defective immune-surveillance in cancer patient’s serum.

Introduction

It is well known that cancer patients exhibit a significant decrease in cellular immune activity which is related to the aggravation of the cancer [1]. This phenomenon of defective immune-surveillance in cancer patients has not been elucidated. I have reported in 1985 why lowering cyclic AMP in his serum is induced defective immune-surveillance from adoptive lymphocyte immunotherapy among cancer patients [2]. Generally speaking, seral cyclic AMP concentration is low in cancer patients. So, immune activity was elevated by the application of adoptive lymphocytes immune therapy after fasting therapy on cancer patients because fasting therapy elevate seral cyclic AMP concentration. Recently, Honjo Tasuku et al., reported why T cell don’t attack cancer cells by the covering of its PD-L1 on T cell receptor, PD-1 [3]. This is also one of defective immune-surveillance from cellular side. I have recently surveyed the concentration between seral cyclic AMP concentration and T cell number and Natural Killer cell. So I have confirmed that low seral cyclic AMP is one of biochemical reason of defective immune-surveillance in cancer patient’s serum.

Best Regards:
Mary Wilson
Journal Manager
Journal of Tumor Research
Email: [email protected]